Monoclonal Antibodies – From Concept to Approval

April 14–15, 2026
IntercityHotel Heidelberg, Heidelberg, Germany

Coriolis Pharma will participate in the “Monoclonal Antibodies – From Concept to Approval” Conference, taking place on April 14–15, 2026 in Heidelberg, Germany, at the IntercityHotel Heidelberg.

The course covers the full lifecycle of monoclonal antibody (mAb) development – from early concepts to manufacturing, analytical characterization, formulation, and regulatory requirements. It also includes an interactive workshop on antibody-drug conjugates (ADCs).

Dr. Andrea Hawe, Chief Scientific Officer at Coriolis Pharma, will join the program as an invited speaker.

Our team will be on site and looks forward to connecting with peers across biologics development.